The main aim of this study was, therefore, to investigate if tau phosphorylation at threonine-212 is an indicator of AD neuropathology, to develop and validate a blood biomarker to quantify these pathological changes, and to compare its performances with that of plasma p-tau217. This evidence concerns the gene MAPT and Alzheimer disease.